癌症研究
表观遗传学
生物
DNA甲基化
白血病
细胞生物学
髓系白血病
癌变
作者
Marissa Rashkovan,Robert Albero,Francesca Gianni,Pablo Perez-Duran,Hannah I Miller,Adam L Mackey,Elisabeth Paietta,Martin S. Tallman,Jacob M. Rowe,Mark R. Litzow,Peter H. Wiernik,Selina M. Luger,Maria Luisa Sulis,Rajesh K Soni,Adolfo A. Ferrando
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2021-10-28
标识
DOI:10.1158/2159-8290.cd-21-0551
摘要
Early T-cell acute lymphoblastic leukemia (ETP-ALL) is an aggressive hematologic malignancy associated with early relapse and poor prognosis that is genetically, immunophenotypically and transcriptionally distinct from more mature T-cell acute lymphoblastic (T-ALL) tumors. Here, we leveraged global metabolomic and transcriptomic profiling of primary ETP and T-ALL leukemia samples to identify specific metabolic circuitries differentially active in this high-risk leukemia group. ETP-ALLs showed increased biosynthesis of phospholipids and sphingolipids, and were specifically sensitive to inhibition of 3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway. Mechanistically, inhibition of cholesterol synthesis inhibited oncogenic AKT1 signaling and suppressed MYC expression via loss of chromatin accessibility at a leukemia stem cell-specific long range MYC enhancer. In all, these results identify the mevalonate pathway as a druggable novel vulnerability in high-risk ETP-ALL cells and uncover an unanticipated critical role for cholesterol biosynthesis in signal transduction and epigenetic circuitries driving leukemia cell growth and survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI